News from Merck KGaA, Sanofi Pasteur, H&P and CADTH – People on the move
Merck KGaA has named Robert Yates as the new president of their Life Sciences division EMD Millipore.
Yates comes to EMD Millipore after recently being appointed head of Roche's Life Science business, where he was responsible for product and portfolio development, global marketing and business strategy and development.
Bernd Reckmann, member of the executive board at Merck, said: “Now, we are entering the next phase of our growth plan focused on delivering value to our customers by driving our pioneering innovation agenda, further penetrating new and established markets and optimizing our infrastructure.
“To fully focus on these activities we decided to appoint a dedicated President of the EMD Millipore division.”
Neurological drug delivery specialists to-BBB has appointed Frederik Lonnqvist as its new chief medical officer.
During his 15-year life science career, Lonnqvist has worked in research, clinical development, translational medicine and business development in several therapeutic areas including Central Nervous System (CNS) diseases such as Alzheimer’s disease and epilepsy.
The announcement came just after Dutch company toBBB announced it has entered the clinic with its brain cancer lead product 2B3-101.
Of his new role, he said: “Considering the potential of to-BBB’s G-Technology for brain drug delivery, I am excited to join the company and further accelerate the development of novel more efficient therapies for patients suffering from severe CNS diseases.”
Aidrian Kilcoyne has become the new UK medical director for Sanofi Pasteur MSD.
Previously he worked for Irish company Roche, where he led the team responsible for issues such as medical affairs, pharmacovigilance, regulatory affairs, medical information and clinical research.
Kilcoyne joins the team just after Sanofi Pasteur was granted prequalification from the World Health Organization for its polysaccharide typhoid vaccine product Typhim Vi.
It is the first therapy of its kind to be granted this status, meaning that a larger number of developing nations that are affected by the disease will be able to gain access to the treatment.
Ipsen today announced the appointment of two new members to the group's executive committee in Nathalie Joannes and Susheel Surpal.
Joannes, formerly on general counsel, international, at Cardinal Health International in Switzerland, will become the new executive VP, general counsel.
And former BEL group corporate financial director Surpal will become the specialty-driven pharmaceutical company’s new executive VP, and CFO.
H&P Industries, an over-the-counter drugs manufacturer, has hired Eamonn Vize as its new chief operating officer.
Vize, former Abbott Laboratories executive, will help the company to restart its manufacturing operations, after it was shut down by the US FDA.
The closure followed H&P’s recall of a number of products since December 2010, including two because of bacterial contamination.
Eric Haertle, H&P president, said: "Eamonn's experience in dealing with the FDA while at Abbott and his strong operational skills will provide tremendous value to our company as we continue our road to recovery.”
Robert Peterson has become chair of newly established Canadian Agency for Drugs and Technologies in Health (CADTH) panel, the Canadian Drug Expert Committee (CDEC).
CDEC consolidates two previous CADTH committees; the Canadian Expert Drug Advisory Committee (CEDAC) and the COMPUS Expert Review Committee (CERC).
And now Peterson – currently the executive director of the Drug Safety and Effectiveness Network – will take on the lead role.
Brian O'Rourke, President and CEO of CADTH said: “Integrating these two roles allows members to combine their expertise, offering both formulary recommendations and advice regarding the appropriate utilization of pharmaceuticals.”
